Q2056 HCPCS Level II code: Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose…
Q2056 is the HCPCS code for “Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
Q2056Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Short description: Ciltacabtagene car-pos t
HCPCS · United States
Medicare details
The indicators CMS publishes with Q2056 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Chemotherapy
- Added
- Oct 1, 2022
Where Q2056 sits
- 1Q codesTemporary codes
- 2Active code Q2056Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code Q2056 mean?
Q2056 is the HCPCS code for “Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover Q2056?
CMS lists Q2056’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q2056
All Q codesQ2049Injection, doxorubicin hydrochloride, liposomal, imported lipodox, 10 mgQ2050Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mgQ2052Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)Q2053Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseQ2054Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseQ2055Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per…Q2057Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic doseQ2058Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusionQ3001Radioelements for brachytherapy, any type, eachQ3014Telehealth originating site facility feeQ3027Injection, interferon beta-1a, 1 mcg for intramuscular useQ3028Injection, interferon beta-1a, 1 mcg for subcutaneous use